Skip to main content
. 2020 Aug 19;28:77–85. doi: 10.1016/j.jare.2020.08.009

Table 2.

Pathological and clinical characteristics of breast cancer samples in relation to metastasis-free survival (MFS).

Non-IBC
IBC
Number of patients (%) Number with metastases (%) MFS p-value a Number of patients (%) Number with metastases (%) MFS p-value a
Total 182 (100) 65 (35.7) 135 (100) 70 (51.9)
Age
≤50 37 (20.3) 10 (27.0) 0.15 (NS) 58 (43.0) 29 (38.6) 0.54 (NS)
>50 145 (79.7) 55 (37.9) 77 (57.0) 41 (41.6)
SBR histological gradeb
I 20 (11.2) 2 (10.0) 0.035c 2 (1.5) 0 (0.0)
II 99 (55.3) 40 (40.4) 48 (36.6) 27 (56.3) 0.44 (NS) d
III 60 (33.5) 23 (38.3) 81 (61.8) 41 (50.6)
Stage
I 16 (8.8) 3 (18.8) 0.00021 0 (0.0) 0 (0.0)
IIA 55 (30.2) 13 (23.6) 0 (0.0) 0 (0.0)
IIB 67 (36.8) 24 (35.8) 0 (0.0) 0 (0.0)
IIIA 35 (19.2) 18 (51.4) 0 (0.0) 0 (0.0)
IIIB 9 (4.9) 7 (77.8) 135 (1 0 0) 70 (51.9)
ER status
Negative 49 (26.9) 13 (26.5) 0.17 (NS) 76 (58.5) 35 (46.1) 0.49 (NS) e
Positive 133 (73.1) 52 (39.1) 54 (41.5) 32 (59.3)
PR status
Negative 77 (42.3) 26 (33.8) 0.94 (NS) 95 (73.6) 49 (51.6) 0.41 (NS) f
Positive 105 (57.7) 39 (37.1) 34 (26.4) 17 (50.0)
ERBB2 status
Negative 149 (81.9) 53 (35.6) 0.94 (NS) 88 (67.7) 50 (56.8) 0.042e
Positive 33 (18.1) 12 (36.4) 42 (32.3) 17 (73.8)
Molecular subtypes
HR- ERBB2- 28 (15.4) 8 (28.6) 0.84 (NS) 39 (30.5) 20 (51.3) 0.19 (NS) h
HR- ERBB2+ 17 (9.3) 5 (29.4) 33 (25.8) 12 (36.4)
HR + ERBB2- 121 (66.5) 45 (37.2) 47 (36.7) 29 (61.7)
HR + ERBB2+ 16 (8.8) 7 (43.8) 9 (7.0) 5 (55.6)

Abbreviations: ER: estrogen receptor alpha; PR: progesterone receptor; ERBB2: human epidermal growth factor receptor 2; HR: hormone receptor. Bold values are statistically significant (p-value < 0.05).

a Log-rank Test; b Scarff-Bloom-Richardson classification; c Information available for 179 patients; d Information available for 131 patients; e Information available for 130 patients; f Information available for 129 patients; h Information available for 128 patients.